Home/Filings/4/0000950142-22-003233
4//SEC Filing

Hurvitz Chaim 4

Accession 0000950142-22-003233

CIK 0001719406other

Filed

Nov 20, 7:00 PM ET

Accepted

Nov 21, 5:58 PM ET

Size

12.8 KB

Accession

0000950142-22-003233

Insider Transaction Report

Form 4
Period: 2022-10-21
Transactions
  • Purchase

    Common Stock

    2022-11-16$0.99/sh+287,812$284,934287,812 total
  • Purchase

    Common Stock

    2022-11-18$1.10/sh+40,408$44,449500,000 total
  • Award

    Employee Stock Option

    2022-10-21+162,660381,083 total
    Exercise: $0.75Exp: 2032-10-21Common Stock (162,660 underlying)
  • Purchase

    Common Stock

    2022-11-17$1.08/sh+171,780$185,522459,592 total
Holdings
  • Common Stock

    (indirect: By IRA)
    1,436,350
  • Common Stock

    (indirect: By CH Health-Private Venture Capital Ltd.)
    208,443
Footnotes (4)
  • [F1]The price reported above reflects the weighted average purchase price per share of common stock (the "Common Stock"), of NRx Pharmaceuticals, Inc. (the "Issuer"). The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.
  • [F2]The price reported above reflects the weighted average purchase price per share of the Common Stock. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.
  • [F3]The price reported above reflects the weighted average purchase price per share of the Common Stock. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common
  • [F4]Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for the Issuer.

Issuer

NRX Pharmaceuticals, Inc.

CIK 0001719406

Entity typeother

Related Parties

1
  • filerCIK 0001630542

Filing Metadata

Form type
4
Filed
Nov 20, 7:00 PM ET
Accepted
Nov 21, 5:58 PM ET
Size
12.8 KB